Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen

Background. Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a longterm cost savings for the additional treatments of conditi...

Full description

Bibliographic Details
Main Authors: Perić Predrag, Antić Branislav, Dinčić Evica, Obradović Dragana, Arsić Stojanka
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2006-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2006/0042-84500602187P.pdf
_version_ 1798045162920738816
author Perić Predrag
Antić Branislav
Dinčić Evica
Obradović Dragana
Arsić Stojanka
author_facet Perić Predrag
Antić Branislav
Dinčić Evica
Obradović Dragana
Arsić Stojanka
author_sort Perić Predrag
collection DOAJ
description Background. Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a longterm cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity. Continuous intrathecal administration of baclofen (ITB), using a subcutaneously implanted programmable infusion pump, is a minimally invasive, reversible method for the treatment of severe diffuse spasticity of the spinal origin. Case report. The first two cases in our country, treated by ITB due to severe spasticity caused by MS, were reported. Despite the local complications of surgical wound healing above the implanted components of the ITB-system in one patient, the optimal reduction of spasticity the with complete elimination of spastic pain was obtained in both patients. Conclusion. Our initial experiences confirmed ITB as a safe and effective therapeutical option for the treatment of intractable spasticity in patients with MS. Major prerequisites for this were adequate patient selection and good control of the basic disease. The use of the minimal invasive implantation technique and the experience in choosing of the adequate ITB-system components, could successfully prevent the occurrence of local complications related to the impaired healing of the ITB-system implantation site.
first_indexed 2024-04-11T23:16:16Z
format Article
id doaj.art-25e3d136825e4069a56f3ca071b6f9d2
institution Directory Open Access Journal
issn 0042-8450
language English
last_indexed 2024-04-11T23:16:16Z
publishDate 2006-01-01
publisher Military Health Department, Ministry of Defance, Serbia
record_format Article
series Vojnosanitetski Pregled
spelling doaj.art-25e3d136825e4069a56f3ca071b6f9d22022-12-22T03:57:36ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502006-01-0163218719110.2298/VSP0602187PTreatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofenPerić PredragAntić BranislavDinčić EvicaObradović DraganaArsić StojankaBackground. Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a longterm cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity. Continuous intrathecal administration of baclofen (ITB), using a subcutaneously implanted programmable infusion pump, is a minimally invasive, reversible method for the treatment of severe diffuse spasticity of the spinal origin. Case report. The first two cases in our country, treated by ITB due to severe spasticity caused by MS, were reported. Despite the local complications of surgical wound healing above the implanted components of the ITB-system in one patient, the optimal reduction of spasticity the with complete elimination of spastic pain was obtained in both patients. Conclusion. Our initial experiences confirmed ITB as a safe and effective therapeutical option for the treatment of intractable spasticity in patients with MS. Major prerequisites for this were adequate patient selection and good control of the basic disease. The use of the minimal invasive implantation technique and the experience in choosing of the adequate ITB-system components, could successfully prevent the occurrence of local complications related to the impaired healing of the ITB-system implantation site.http://www.doiserbia.nb.rs/img/doi/0042-8450/2006/0042-84500602187P.pdfmultiple sclerosismuscle spasticitybaclofeninfusionpumpsinjections spinal
spellingShingle Perić Predrag
Antić Branislav
Dinčić Evica
Obradović Dragana
Arsić Stojanka
Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
Vojnosanitetski Pregled
multiple sclerosis
muscle spasticity
baclofen
infusionpumps
injections spinal
title Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
title_full Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
title_fullStr Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
title_full_unstemmed Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
title_short Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
title_sort treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen
topic multiple sclerosis
muscle spasticity
baclofen
infusionpumps
injections spinal
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2006/0042-84500602187P.pdf
work_keys_str_mv AT pericpredrag treatmentofseverespacticityinmultiplesclerosisbycontinuousintrathecalbaclofen
AT anticbranislav treatmentofseverespacticityinmultiplesclerosisbycontinuousintrathecalbaclofen
AT dincicevica treatmentofseverespacticityinmultiplesclerosisbycontinuousintrathecalbaclofen
AT obradovicdragana treatmentofseverespacticityinmultiplesclerosisbycontinuousintrathecalbaclofen
AT arsicstojanka treatmentofseverespacticityinmultiplesclerosisbycontinuousintrathecalbaclofen